Ixempra (ixabepilone; R-Pharm/Otsuka) is a lactam analog of epothilone B that binds to microtubules via tubulin. The binding of Ixempra to tubulin results in mitotic arrest of cells at G2-M followed by p53- and Bax-dependent apoptosis.
Datamonitor Healthcare does not expect Ixempra (ixabepilone; R-Pharm/Otsuka) revenues to grow significantly in the near future. Ixempra has not been a commercial success in breast cancer treatment, with peak revenues of only $117m in 2010 since its approval in 2007. Ixempra was acquired by R-Pharm from Bristol-Myers Squibb in 2015 and R-Pharm’s relative lack of oncology marketing experience and commercial resources could be detrimental to the drug’s growth. Ixempra faces competition from several late-phase candidates that may reach the market as early as 2016, and it could also face generic competition from 2018 after the expiration of key patents.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Ixempra : Breast cancer: HR+/HER2-
LIST OF FIGURES
12 Figure 1: Ixempra for HR+/HER2- breast cancer – SWOT analysis
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of Ixempra in HR+/HER2-
13 Figure 3: Datamonitor Healthcare’s drug assessment summary of Ixempra in HR+/HER2-
LIST OF TABLES
4 Table 1: Ixempra drug profile
7 Table 2: Ixempra pivotal trial data in HR+/HER2- breast cancer
11 Table 3: Ixempra late-phase trial data in HR+/HER2- breast cancer
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.